Spironolactone for Reducing Proteinuria in Diabetic Nephropathy
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Introduction: Aldosterone seems to have deleterious effects on the kidneys. Many animal
studies and few clinical trials now have shown that suppression of aldosterone by aldosterone
receptor blockers ameliorated these effects.
Method: In a double-blind, cross over study, 24 patients with diabetic nephropathy who were
already receiving either ACE inhibitor(lisinopril 20-40 mg/day ) or ARB( losartan 25-100
mg/day )were given spironolactone( 25 mg during the first month and 50 mg during the second
and third month if serum K remained ok) or matching placebo with 1 month of washout in
between. All patients were from a single center and exclusively male veterans. Blood
pressure, serum creatinine, serum K and spot urine protein/creatinine were measured at the
beginning and end of each study period. The study was started in May of 2003 and completed in
May 2006.
Phase:
N/A
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development